Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Fig. 3

Best tumor response. Best tumor responses are shown using colored bars in this waterfall plot. The y-axis reflects percentage change in maximal tumor size compared to baseline in target lesions, and bar colors indicate overall best response. *BROR-01 had clinical progression 3 weeks after treatment initiation requiring study discontinuation before the first imaging assessment

Back to article page